These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

388 related items for PubMed ID: 30374685

  • 1. Respiratory syncytial virus (RSV) infection in children with medical complexity.
    Lim A, Butt ML, Dix J, Elliott L, Paes B.
    Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
    [Abstract] [Full Text] [Related]

  • 2. Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab.
    Wang DY, Saleem M, Paes BA, Mitchell I, Li A, Lanctôt KL, CARESS Investigators.
    Pediatr Infect Dis J; 2019 Aug; 38(8):775-780. PubMed ID: 30985509
    [Abstract] [Full Text] [Related]

  • 3. Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005-2017.
    Kim D, Saleem M, Paes B, Mitchell I, Lanctôt KL.
    Clin Infect Dis; 2019 Aug 30; 69(6):980-986. PubMed ID: 30517603
    [Abstract] [Full Text] [Related]

  • 4. Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders.
    Paes B, Kim D, Saleem M, Wong S, Mitchell I, Lanctot KL, and the CARESS investigators.
    Eur J Pediatr; 2019 Mar 30; 178(3):377-385. PubMed ID: 30610419
    [Abstract] [Full Text] [Related]

  • 5. Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Bjornson C, Chan P, Li A, Paes B, Lanctôt KL, Mitchell I.
    Eur J Clin Microbiol Infect Dis; 2018 Jun 30; 37(6):1113-1118. PubMed ID: 29557081
    [Abstract] [Full Text] [Related]

  • 6. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
    Paes B, Saleem M, Kim D, Lanctôt KL, Mitchell I.
    Eur J Clin Microbiol Infect Dis; 2019 Aug 30; 38(8):1561-1568. PubMed ID: 31119575
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children: Outcomes From the Canadian RSV Evaluation Study of Palivizumab Registry Over Twelve Seasons (2005-2017).
    Paes BA, Saleem M, Li A, Lanctôt KL, Mitchell I, CARESS Investigators.
    Pediatr Infect Dis J; 2020 Jun 30; 39(6):539-545. PubMed ID: 32235248
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR.
    Pediatr Infect Dis J; 2003 Feb 30; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [Abstract] [Full Text] [Related]

  • 12. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
    Mitchell I, Li A, Bjornson CL, Lanctot KL, Paes BA, CARESS investigators.
    Am J Perinatol; 2022 Nov 30; 39(15):1668-1677. PubMed ID: 33657636
    [Abstract] [Full Text] [Related]

  • 13. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
    Manzoni P, Paes B, Lanctôt KL, Dall'Agnola A, Mitchell I, Calabrese S, Maule M, Girardi E, Harimoto T, Li A.
    Pediatr Infect Dis J; 2017 Jan 30; 36(1):2-8. PubMed ID: 27649365
    [Abstract] [Full Text] [Related]

  • 14. Respiratory Syncytial Virus Infection-associated Hospitalization Rates in Infants and Children With Cystic Fibrosis.
    Metz J, Eber E, Resch B.
    Pediatr Infect Dis J; 2017 Jun 30; 36(6):545-548. PubMed ID: 28005688
    [Abstract] [Full Text] [Related]

  • 15. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 30; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 16. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
    Forbes ML, Kumar VR, Yogev R, Wu X, Robbie GJ, Ambrose CS.
    Hum Vaccin Immunother; 2014 Sep 30; 10(10):2789-94. PubMed ID: 25483663
    [Abstract] [Full Text] [Related]

  • 17. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.
    Paes B, Mitchell I, Yi H, Li A, Lanctôt KL, CARESS Investigators.
    Pediatr Infect Dis J; 2014 Feb 30; 33(2):e29-33. PubMed ID: 23989104
    [Abstract] [Full Text] [Related]

  • 18. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP, Lee SWH.
    Pharmacotherapy; 2017 Jun 30; 37(6):755-769. PubMed ID: 28423192
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.